HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robbins, R. J. Articles by Schlumberger, M. J. Search for Related Content PubMed PubMed Citation Articles by Robbins, R. J. Articles by Schlumberger, M. J.

The Evolving Role of ¹³¹I for the Treatment of Differentiated Thyroid Carcinoma

¹ Endocrine Service, Division of General Medicine, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
² Service de Medecine Nucleaire, Institut Gustave Roussy, Villejuif, France

The use of radioactive iodine (¹³¹I) for the treatment of thyroid carcinoma has changed over the past 50 y. These changes are based on increasing awareness of the biophysical properties of ¹³¹I and new discoveries concerning the biology of iodine handling by thyroid cells. The therapeutic administration of ¹³¹I for thyroid remnant ablation and for metastases requires an appreciation of iodine clearance kinetics, of factors that can alter the occupancy time of ¹³¹I within lesions, and of the role of thyroid-stimulating hormone in stimulating the sodium-iodide symporter. The potential complications and adverse events associated with ¹³¹I are discussed. ¹³¹I will continue to be a major weapon in the fight against metastatic thyroid carcinoma. Its future role will be modified by expanding knowledge of its relative risks and benefits.

Key Words: thyroid carcinoma • radioactive iodine • dosimetry • metastases • adverse effects • carcinogenesis

This article has been cited by other articles:

				G. Sgouros, H. Song, P. W. Ladenson, and R. L. Wahl Lung Toxicity in Radioiodine Therapy of Thyroid Carcinoma: Development of a Dose-Rate Method and Dosimetric Implications of the 80-mCi Rule J. Nucl. Med., December 1, 2006; 47(12): 1977 - 1984. [Abstract] [Full Text] [PDF]

				H. Song, B. He, A. Prideaux, Y. Du, E. Frey, W. Kasecamp, P. W. Ladenson, R. L. Wahl, and G. Sgouros Lung Dosimetry for Radioiodine Treatment Planning in the Case of Diffuse Lung Metastases J. Nucl. Med., December 1, 2006; 47(12): 1985 - 1994. [Abstract] [Full Text] [PDF]

				R. M. Tuttle, R. Leboeuf, R. J. Robbins, R. Qualey, K. Pentlow, S. M. Larson, and C. Y. Chan Empiric Radioactive Iodine Dosing Regimens Frequently Exceed Maximum Tolerated Activity Levels in Elderly Patients with Thyroid Cancer J. Nucl. Med., October 1, 2006; 47(10): 1587 - 1591. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659. [Abstract] [Full Text] [PDF]